XNAS · TXG
-1.66% · -$0.7400 · Vol 2.6M
Market closed · last close 4:00 PM ET · price as of 16:48:38 ET
10x Genomics, Inc. Class A Common Stock

10x Genomics, Inc. Class A Common Stock

LABORATORY ANALYTICAL INSTRUMENTS
$43.74
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

Score not reportedVeridion does not publish a score-history trend for TXG until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
NO SCORE SNAPSHOT COVERAGE
AI Analysis
Sovereign

Why is TXG moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for TXG are being assembled.
About 10x Genomics, Inc. Class A Common Stock
LABORATORY ANALYTICAL INSTRUMENTS
Listed since
2019
Employees
1K
Country
US

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$43.44
Day high
$44.48
Day low
$42.75
Previous close
$44.48
52W high
$45.79
-4.48% from high
52W low
$11.34
94% of range
Market cap
$5.6B
EPS
$-0.3200
Beta
2.43
Shares out
127M
Volume
2.6M
0.74× rel vol
Avg volume
3.5M
VWAP
$43.56
Price history computed in-house
1W
+2.36%
1M
+25.85%
3M
+77.88%
1Y
+260.00%
YTD
+168.18%
SMA 50 $31.54 · above
SMA 200 $21.62 · above
52W position 94%
Veridion warehouse edge

Warehouse intelligence for TXG.

Veridion Score
Not reported
Six-factor detail requires Sovereign.
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the TXG research trail.

Relationship mapTrace receipt-backed holders and filings around TXG.Congress trackerSearch the public STOCK Act disclosure ledger.Thematic mapTechBio & AI Drug DiscoveryMethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

Receipt-backed filing rows for TXG are being assembled from the latest scheduled snapshot.

Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

TXG contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TXG in this window.
Lobbying spend

TXG lobbying filings, year to date.

Registered lobbying filings matched to 10x Genomics, Inc. Class A Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TXG in this window.
Latest news · TXG
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for TXG.
Options
Sovereign unlock shows live options positioning for TXG.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.